Evidence map›Paper›PMID 42717145›Full record

ArticleThe AAPS journal2026

Exploring a Persistent Terbinafine - CYP2D6 Interaction Using Physiologically - Based Pharmacokinetic Modeling.

Devendra Pade, Jan Wahlstrom

Abstract read
PubMed Publisher
In one paragraph

Article in The AAPS journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Devendra PadePharmacokinetics and Drug Metabolism, Amgen Inc., Cambridge, Massachusetts, 02142, USA.ORCID http://orcid.org/0000-0003-0709-9528
Jan WahlstromPharmacokinetics and Drug Metabolism, Amgen Inc., Thousand Oaks, California, 91320, USA. janw@amgen.com.ORCID http://orcid.org/0000-0002-9434-1302

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Terbinafine (TBNF), a lipophilic anti-fungal agent prescribed for onychomycosis distributes extensively into adipose, skin and peripheral tissues. TBNF and metabolite desmethyl terbinafine (DMT) are potent inhibitors of CYP2D6. A combination of prolonged half-life and CYP2D6 inhibition causes clinically significant interactions with drugs involving CYP2D6 metabolism that may persist for weeks after dosing cessation. A physiologically based pharmacokinetic (PBPK) model for TBNF and DMT incorporating in vitro and clinical information was developed and verified to predict their steady state pharmacokinetics. Experimentally determined Ki

Indexed as

Antifungal AgentsCytochrome P-450 CYP2D6Cytochrome P-450 CYP2D6 InhibitorsModels, BiologicalNaphthalenesTerbinafineDrug InteractionsHumansAntifungal AgentsCytochrome P-450 CYP2D6Cytochrome P-450 CYP2D6 InhibitorsNaphthalenesTerbinafinedesmethyl terbinafinePBPK CYP2D6 DDIterbinafine

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.